Effects of CNTO 530, an erythropoietin mimetic-IgG4 fusion protein, on embryofetal development in rats and rabbits

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 89, Issue 2, 2010, Pages 87-96

  Martin, Pauline L ^a   Sachs, Clifford ^a   Hoberman, Alan ^b   Jiao, Qun ^a   Bugelski, Peter J ^a  

^a CENTOCOR INC   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

Antibody; CNTO 530; Embryofetal development; Erythropoietin; FcRn; Fetal exposure; IgG4; Rabbit; Rat

Indexed keywords

CNTO 530; ERYTHROPOIETIN; HYBRID PROTEIN; IMMUNOGLOBULIN G4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CESAREAN SECTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; EMBRYO DEVELOPMENT; ERYTHROCYTE; ERYTHROPOIESIS; FEMALE; FETUS DEVELOPMENT; GESTATIONAL AGE; HEMATOCRIT; MALE; NONHUMAN; ORGANOGENESIS; PRIORITY JOURNAL; RABBIT; RAT;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; BODY WEIGHT; BONE AND BONES; EMBRYO, MAMMALIAN; EMBRYONIC DEVELOPMENT; FEMALE; FETAL DEVELOPMENT; FETAL WEIGHT; INJECTIONS, SUBCUTANEOUS; OSTEOGENESIS; POLYCYTHEMIA; PREGNANCY; RABBITS; RATS; RECEPTORS, ERYTHROPOIETIN; RECOMBINANT FUSION PROTEINS; TERATOGENS;

ORYCTOLAGUS CUNICULUS; RATTUS;

EID: 77951732265     PISSN: 15429733     EISSN: 15429741     Source Type: Journal    
DOI: 10.1002/bdrb.20227     Document Type: Article

References (26)

1. Bugelski PJ, Capocasale RJ, Makropoulos D, Marshall D, Fisher PW, Lu J, Achuthanandam R, Spinka-Doms T, Kwok D, Graden D, Volk A, Nesspor T, James IE, Huang C. 2008. CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice. J Biotechnol 134:171-180.
2. Clarke J, Leach W, Pippig S, Joshi A, Wu B, House R, Beyer J. 2004. Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody. Reg Toxicol Pharmacol 40:219-226. (Pubitemid 39531303)
3. Dancis J, Lind J, Oratz M, Smolens J, Vara P. 1961. Placental transfer of proteins in human gestation. Am J Obstet Gynecol 82:167-171.
4. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. 2003. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31:290-299. (Pubitemid 36407605)
5. Fujimoto K, Terao K, Cho F, Honjo S. 1983. The placental transfer of IgG in the cynomolgus monkey. Japan J Med Sci Biol 36:171-176.
6. Ghetie V, Ward ES. 2002. Transcytosis and catabolism of antibody. Immunol Res 25:97-113.
7. Goshorn J, Youell TD. 2005. Darbepoetin alfa treatment for post-renal transplantation anemia during pregnancy. J Kidney Dis 46:E81-E86.
8. Halliday R. 1955. Prenatal and postnatal transmission of passive immunity to young rats. Proc R Soc B 143:408-413.
9. Jauniaux E, Jurkovic D, Gulbis B, Liesnard C, Lees C, Campbell S. 1995. Materno-fetal immunoglobulin transfer and passive immunity during the first trimester of human pregnancy. Human Reprod 10:3297-3300. (Pubitemid 26027278)
10. Malek A, Sager R, Eckardt KU, Bauer C, Schneider H. 1994. Lack of transport of erythropoietin across the human placenta as studied by an in vitro perfusion system. Pflugers Arch Eur J Physiol 427:1432-2013. (Pubitemid 24131567)
11. Malek A, Sager R, Kuhn P, Nicholaides KH, Schneider H. 1996. Evaluation of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 36:248-255. (Pubitemid 26383975)
12. Martin PL, Cornacoff JB, Treacy G, Eirikas E, Marin J, White KL, Peachee V, Hoberman A. 2008. Effects of administration of a monoclonal antibody against tumor necrosis factor alpha during pregnancy and lactation on the pre- and postnatal development of the mouse immune system. Int J Toxicol 27:341-347.
13. Martinez-Morales S, Bonillo-Perales A, Munoz-Hoyos A, Puertas-Prieto A, Uberos-Fernandez J, Molina-Carballo A, Bonillo-Perales JC, Sabatel-Lopez R. 1999. The influence of maternal erythrocyte deformability on fetal growth, gestational age and birth weight. J Perinatal Med 27:166-172. (Pubitemid 29348649)
14. Morphis LG, Gitlin D. 1970. Maturation of the maternofetal transport system for γ-globulin in the mouse. Nature 228:573.
15. Palfi M, Selbing A. 1998. Placental transport of maternal immunoglobulin G. Am J Reprod Immunol 39:24-26.
16. Pentsuk N, van der Laan W. 2009. An interspecies comparison of placental antibody transfer: New insights into developmental toxicity testing of monoclonal antibodies. Birth Def Res B 86:328-344.
17. Reisenberger K, Egarter C, Kapiotis S, Sternberger B, Gregor H, Husslein P. 1997. Transfer of erythropoietin across the placenta perfused in vitro. Obstet Gynecol 89:738-742. (Pubitemid 27184857)
18. Ridley DM, Dawkins F, Perlin E. 1994. Erythropoietin: a review. J Natl Med Assoc 86:129-135.
19. Roopenian DC, Akilesh S. 2007. FcRn: the neonatal Fc receptor comes of age. Nature Rev Immunol 7:715-725. (Pubitemid 47327396)
20. Sathyanarayana P, Houde E, Marshall D, Volk A, Makropoulos D, Emerson C, Pradeep A, Bugelski PJ, Wojchowski DM. 2009. CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools. Blood 113:4955-4962.
21. Schneider H, Malek A. 1995. Lack of permeability of the human placenta for erythropoietin. J Perinatal Med 23:71-76.
22. Sifakis S, Angelakis E, Vardaki E, Koumantaki Y, Matalliotakis I, Koumantakis E. 2001. Erythropoietin in the treatment of iron deficiency anemia during pregnancy. Gynecol Obstet Invest 51:150-156. (Pubitemid 32304734)
23. Simister NE. 2003. Placental transport of immunoglobulin G. Vaccine 21:3365-3369.
24. Sobilo-Jarek L, Popowsko-Drojecka J, Muszytowski M, Wanic-Kossowaska M, Kobelski M, Czekalski S. 2006. Anemia treatment with darbepoetin alpha in pregnant female with chronic renal failure: report of two cases. Adv Med Sci 51:309-311.
25. Verdier F, Barrow PC, Burge J. 2003. Reproductive toxicity testing of vaccines. Toxicology 185:213-219.
26. Zanjani ED, Pixley JS, Slotnick N, MacKintosh R, Ekhterae D, Demons G. 1993. Erythropoietin dose not cross the placenta into the fetus. Pathobiology 61:211-215. (Pubitemid 23274189)